Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Huddart

Showing results (81-90 of 111) with videos related to

Pageof 12
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 9, 2020
Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinomaYohann Loriot, Cora N Sternberg, Daniel Castellano, et al.
European Urology|May 15, 2018
Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System)Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al.
Journal of the National Cancer Institute|February 3, 2025
Factors associated with longitudinal progression of the cumulative burden of morbidity and overall mortality after cisplatin-based chemotherapy for testicular cancerSarah L Kerns, Paul C Dinh, Patrick O Monahan, et al.
European Urology Oncology|February 6, 2025
Redefining Good-prognosis Seminoma: Implications for Clinical Practice of the Updated International Germ Cell Cancer Collaborative Group Classification and Results from the SEMITrends SurveyAnna Patrikidou, Christoph Oing, Christos Markellos, et al.
JNCI Cancer Spectrum|August 14, 2024
Cognitive function in long-term testicular cancer survivors: impact of modifiable factorsPaul C Dinh, Patrick O Monahan, Chunkit Fung, et al.
The Lancet. Oncology|December 16, 2011
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trialDavid Dearnaley, Isabel Syndikus, Georges Sumo, et al.
JNCI Cancer Spectrum|July 25, 2020
Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer SurvivorsSarah L Kerns, Chunkit Fung, Sophie D Fossa, et al.
BMJ Open|January 1, 2021
Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidanceShaista Hafeez, Amanda Webster, Vibeke N Hansen, et al.
British Journal of Cancer|June 2, 2026
Risk factors and causes of early death in germ cell tumors: a Global Society for Rare GU tumors studyMichal Mego, Edgar Israelyan, Robert J Hamilton, et al.
The New England Journal of Medicine|July 25, 2019
Erdafitinib in Locally Advanced or Metastatic Urothelial CarcinomaYohann Loriot, Andrea Necchi, Se Hoon Park, et al.
Pageof 12

Showing results (81-90 of 111) with videos related to

Sort By:
Pageof 12
European Journal of Cancer (Oxford, England : 1990)|September 9, 2020
Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinomaYohann Loriot, Cora N Sternberg, Daniel Castellano, et al.
European Urology|May 15, 2018
Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System)Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al.
Journal of the National Cancer Institute|February 3, 2025
Factors associated with longitudinal progression of the cumulative burden of morbidity and overall mortality after cisplatin-based chemotherapy for testicular cancerSarah L Kerns, Paul C Dinh, Patrick O Monahan, et al.
European Urology Oncology|February 6, 2025
Redefining Good-prognosis Seminoma: Implications for Clinical Practice of the Updated International Germ Cell Cancer Collaborative Group Classification and Results from the SEMITrends SurveyAnna Patrikidou, Christoph Oing, Christos Markellos, et al.
JNCI Cancer Spectrum|August 14, 2024
Cognitive function in long-term testicular cancer survivors: impact of modifiable factorsPaul C Dinh, Patrick O Monahan, Chunkit Fung, et al.
The Lancet. Oncology|December 16, 2011
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trialDavid Dearnaley, Isabel Syndikus, Georges Sumo, et al.
JNCI Cancer Spectrum|July 25, 2020
Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer SurvivorsSarah L Kerns, Chunkit Fung, Sophie D Fossa, et al.
BMJ Open|January 1, 2021
Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidanceShaista Hafeez, Amanda Webster, Vibeke N Hansen, et al.
British Journal of Cancer|June 2, 2026
Risk factors and causes of early death in germ cell tumors: a Global Society for Rare GU tumors studyMichal Mego, Edgar Israelyan, Robert J Hamilton, et al.
The New England Journal of Medicine|July 25, 2019
Erdafitinib in Locally Advanced or Metastatic Urothelial CarcinomaYohann Loriot, Andrea Necchi, Se Hoon Park, et al.
Pageof 12